Unique ID issued by UMIN | UMIN000049429 |
---|---|
Receipt number | R000056280 |
Scientific Title | A feasible Study on the measurement of blood levels of anti-cancer drugs |
Date of disclosure of the study information | 2022/11/04 |
Last modified on | 2022/11/04 15:08:53 |
A feasible Study on the measurement of blood levels of anti-cancer drugs
A feasible Study on the measurement of blood levels of anti-cancer drugs
A feasible Study on the measurement of blood levels of anti-cancer drugs
A feasible Study on the measurement of blood levels of anti-cancer drugs
Japan |
cancer
Hematology and clinical oncology |
Malignancy
NO
Blood levels of drugs will be measured using blood from cancer patients receiving anticancer drugs to evaluate the feasibility of therapeutic drug monitoring (TDM) in clinical settings.
Based on the results of this study, we will evaluate the feasibility of a trial to test the clinical benefits of blood drug monitoring for drugs with high blood drug concentration variability, the elderly, and patients with organ dysfunction.
Safety,Efficacy
Assess whether measurement data by the pharmacist can be achieved within 90 minutes of specimen submission at each patient's first measurement of blood levels of antineoplastic drugs.
Observational
1 | years-old | <= |
100 | years-old | > |
Male and Female
(i)The patient is scheduled to be treated or is being treated with the anti-cancer drugs at the National Cancer Center Hospital.
ex.
Axitinib, abemaciclib, ibrutinib, imatinib, osimertinib, olaparib, cabozantinib, sunitinib, pazopanib, palbociclib, brigatinib, venetoclax, regorafenib, lenvatinib, lorlatinib, etc.
(ii) Adults whose written consent to the study has been obtained by the individual, or minors 16 years of age or older whose written consent to the study has been obtained by the individual and/or a surrogate
(1) Patients who are determined to be ineligible for this study by the principal investigator or the study office
(2) Patients with active blood-borne infection (HIV, HBV, HCV, etc.) when measured by the DPS method
65
1st name | Yuki |
Middle name | |
Last name | Katsuya |
National cancer center hospital
Department of experimental development
1040045
5-1-1, Chuo-ku, Tsukiji, Tokyo
0335422511
ykatsuya@ncc.go.jp
1st name | Yuki |
Middle name | |
Last name | Katsuya |
National Cancer Center Hospital
Department of experimental development
1040045
5-1-1, Chuo-ku, Tsukiji, Tokyo
0335422511
ykatsuya@ncc.go.jp
National cancer center hospital
National cancer center hospital
Self funding
National cancer center
5-1-1, Tsukiji, Chuo-ku
0335422511
irst@ml.res.ncc.go.jp
YES
2021-386
Natinal cancer center
2022 | Year | 11 | Month | 04 | Day |
Unpublished
Enrolling by invitation
2022 | Year | 01 | Month | 20 | Day |
2022 | Year | 02 | Month | 28 | Day |
2022 | Year | 03 | Month | 04 | Day |
2024 | Year | 12 | Month | 31 | Day |
Blood levels of drugs will be measured using blood from cancer patients receiving antineoplastic drugs to evaluate the feasibility of therapeutic drug monitoring (TDM) in clinical settings.
Based on the results of this study, we will evaluate the feasibility of a trial to test the clinical benefits of blood drug monitoring for drugs with high blood drug concentration variability, the elderly, and patients with organ dysfunction.
2022 | Year | 11 | Month | 04 | Day |
2022 | Year | 11 | Month | 04 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000056280
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |